her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant; her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant; No adverse event; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant) and NO ADVERSE EVENT (No adverse event) in a 29-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. The patient's last menstrual period was in November 2022 and the estimated date of delivery was on an unknown date. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant) and NO ADVERSE EVENT (No adverse event). The patient received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) beginning around the  fifth month of the pregnancy.  At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant) had resolved and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for MATERNAL EXPOSURE DURING PREGNANCY (her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (her first Moderna Covid -19 vaccine on April 6, 2023 patient received in her right arm lot number patient is 4 months pregnant/received her first booster dose of Moderna Covid-19 patient received in right arm Patient is 5 months pregnant).    No concomitant and treatment medications were reported.  Company Comment: This spontaneous case concerns a 29-year-old female patient, with no medical history reported, who experienced non serious unexpected event Maternal exposure during pregnancy and Inappropriate schedule of product administration with No adverse event that occurred in association with a dose (reported as first booster) of mRNA-1273.222 (Original/Omicron BA.4/5) vaccine. Patient received vaccination in her right arm at 4 months of gestation and she received her first booster dose at 5 months gestation. Details regarding estimated date of delivery were not provided. The benefit-risk relationship of mRNA-1273.222 (Original/Omicron BA.4/5) vaccine is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2023-723072 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-723072:Monovalent suspect case